medigraphic.com
Instituto Nacional de Salud Pública

2003, Number 4

Next >>

salud publica mex 2003; 45 (4)

Letters to editor

Language: English
References: 34
Page: 243-244
PDF size: 126.90 Kb.


Text Extraction

Are imidazolic drugs effective in the treatment of chronic Chagas cardiomyopathy?

To the editor: In 1909 Carlos Chagas described American Trypanosomiasis (AT), or hagas disease. Today this disease is still a major threat to public health in Latin merican countries. In 1991 the World Health Organization reported that approximately 8 million people were infected, and another 100 million were potentially at risk. Since hen, the Health Ministries of Argentina, Brazil, Bolivia, Chile, Paraguay, and Uruguay created the South Cone Initiative to eliminate vectorial and transfusional Chagas disease transmission by year 2010. This initiative has spread to other South and Central American countries. The accomplishments so far are remarkable: some countries have been declared free of vectorial transmission, and others are very close to reaching this goal.


REFERENCES

  1. World Health Organization. Control of Chagas disease. Report of a WHO expert committee. Ginebra: WHO, WHO Technical report series No. 811, 1991.

  2. Schofield CJ, Dias JC. The Southern Cone initiative against Chagas disease. Adv Parasitol 1999;42:1-27.

  3. Guzmán-Bracho C. Epidemiology of Chagas disease in Mexico: An update. Trend Parasit 2001;17:372-376.

  4. Dumonteil E. Update on Chagas disease in Mexico. Salud Publica Mex 1999;41:322-327.

  5. Secretaría de Salud. Norma técnica No 348, para la prevención y control de la tripanosomiasis en la atención primaria a la salud. México, DF: Diario Oficial de la Federación, 17 enero 1992.

  6. Brener Z. Chemotherapy of Trypanosoma cruzi infection. Arch Pharmacol Chemother 1975;13:13-44.

  7. Cancado JR. Long-term evaluation of etiological treatment of Chagas disease with

  8. benznidazole. Rev Inst Med Trop S Paulo 2002;44:29-37.

  9. Andrade SS, Guimaraes J. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(23):1407-1413.

  10. Sosa S, Segura EL, Mariano A, Velázquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 1998;59(4):526-529.

  11. Stoppani AOM. Quimioterapia de la enfermedad de Chagas. Medicina 1999;59(supl II):147-165.

  12. Reyes P, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Cochrane Protocol). In: The Cochrane Library. Oxford: Update Software, 2003.

  13. Rodriguez-Coura J, De Abreu LL, Percy H, Wilcox F, Petana W. Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crónica da doenca de Chagas, em uma área de campo com trasmissao interrompida. I. Evaluacao preliminar. Rev Soc Bras Med Trop 1997;30:139-144.

  14. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994;127:151-162.

  15. 14.Fabro D, Arias E, Streiger M, Placenza M, Ingaramo M, Del Barco M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop S Paulo 2000;42:99-109.

  16. Braga MS, Lauria-Pires L, Arganaraz ER, Nascemento RJ, Teixeira ARL. Persistent

  17. infection in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop S Paulo 2000; 42: 157-161.

  18. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63:111-118.

  19. World Health Organization. Control of Chagas disease. Report of a WHO expert committee. Ginebra: WHO, WHO Technical report series No. 811, 1991.

  20. Schofield CJ, Dias JC. The Southern Cone initiative against Chagas disease. Adv Parasitol 1999;42:1-27.

  21. Guzmán-Bracho C. Epidemiology of Chagas disease in Mexico: An update. Trend Parasit 2001;17:372-376.

  22. Dumonteil E. Update on Chagas disease in Mexico. Salud Publica Mex 1999;41:322-327.

  23. Secretaría de Salud. Norma técnica No 348, para la prevención y control de la tripanosomiasis en la atención primaria a la salud. México, DF: Diario Oficial de la Federación, 17 enero 1992.

  24. Brener Z. Chemotherapy of Trypanosoma cruzi infection. Arch Pharmacol Chemother 1975;13:13-44.

  25. Cancado JR. Long-term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop S Paulo 2002;44:29-37.

  26. Andrade SS, Guimaraes J. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996;348(23):1407-1413.

  27. Sosa S, Segura EL, Mariano A, Velázquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 1998;59(4):526-529.

  28. Stoppani AOM. Quimioterapia de la enfermedad de Chagas. Medicina 1999;59(supl II):147-165.

  29. Reyes P, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Cochrane Protocol). In: The Cochrane Library. Oxford: Update Software, 2003.

  30. Rodriguez-Coura J, De Abreu LL, Percy H, Wilcox F, Petana W. Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crónica da doenca de Chagas, em uma área de campo com trasmissao interrompida. I. Evaluacao preliminar. Rev Soc Bras Med Trop 1997;30:139-144.

  31. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas disease with benznidazole: Clinical and serological evolution of patients with long-term follow-up. Am Heart J 1994;127:151-162.

  32. 14.Fabro D, Arias E, Streiger M, Placenza M, Ingaramo M, Del Barco M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop S Paulo 2000;42:99-109.

  33. Braga MS, Lauria-Pires L, Arganaraz ER, Nascemento RJ, Teixeira ARL. Persistent infection in chronic Chagas disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev Inst Med Trop S Paulo 2000; 42: 157-161.

  34. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 2000;63:111-118.




2020     |     www.medigraphic.com